The mission of the MP1U is to develop and utilize robust pre-clinical and in-vivo systems for the testing of novel cancer therapeutics
The UNC MP1U was established in 2006 to facilitate the pre-clinical development of novel anti-cancer therapeutics in highly faithful genetically engineered murine models (GEMM) of human cancer. Since then, efforts have expanded into developing and characterizing robust syngeneic models in conjunction with our GEMMs. The MP1U oversight includes two distinguished faculty Directors (Charles Perou, Ph.D. and William Y. Kim, M.D.), program director, laboratory operations manager, project manager, and 2 full time animal handlers with a combined total of over 60 years of murine research experience.
Leader, Pre-clinical Immunotherapy Program
The MP1U has developed considerable institutional infrastructure to facilitate pre-clinical research. Veterinary care and laboratory animal management is supported by UNC’s Division of Comparative Medicine (DCM) who has been accredited by the Association for the Assessment of Accreditation of Laboratory Animal Care (AAALAC) International since 1973. We aim to provide several bespoke pre-clinical study options driven by the collaborator’s research goals. More details pertaining to this service can be found in the “Collaboration Development” section of the “Contact” tab.
Pre-clinical Study Options
- Maximum Tolerated Dose
- Therapeutic Efficacy
- Clinical Chemistry test
- Non-invasive imaging modalities
- Protocol Assistance: UNC_IACUC and MP1U internal
- Therapeutic delivery methods
- Tissue/Blood collection
- Tumor measurements by manual caliper
- Serial passage of tumor material: dissociated single cell & fragment
- Pharmacodynamics / Pharmacokinetics
Additionally, the MP1U has the capability to coordinate the integration of other UNC core expertise to facilitate additional data collection and technical services.
Associated Cores Facilities